Infectious Disease Advisor news story
Among children and adolescents living with HIV, dolutegravir (DTG)-based antiretroviral therapy (ART) demonstrates sustained superior efficacy compared with non-dolutegravir standard care regimens over 240 weeks, according to study findings published in Open Forum Infectious Diseases.
Researchers conducted the ODYSSEY randomized clinical trial (ClinicalTrials.gov Identifier: NCT02259127) to evaluate the long-term efficacy and safety of DTG-based ART among infants, children, and adolescents living with HIV who were either initiating first-line therapy or switching to second-line treatment after virologic failure.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.